The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

The American Cancer Society’s Colleges Against Cancer program at Shippensburg University hosted its annual Relay for Life ...

Results of study directed by Rodrigo Toledo, Head of the Vall d'Hebron Institute of Oncology's (VHIO) Biomarkers and Clonal ...

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...